EN | UA
EN | UA

Help Support

Back

Vitamin-D3 Supplementation shows effectiveness in reducing migraine days in Migraine patients

Vitamin-D3 Supplementation shows effectiveness in reducing migraine days in Migraine patients Vitamin-D3 Supplementation shows effectiveness in reducing migraine days in Migraine patients
Vitamin-D3 Supplementation shows effectiveness in reducing migraine days in Migraine patients Vitamin-D3 Supplementation shows effectiveness in reducing migraine days in Migraine patients

What's new?

Supplementing migraine patients with vitamin D3 helps in reducing migraine frequency and number of migraine days.

As per a recent randomized, double-blinded, placebo-controlled parallel analysis led by P. Gazerani and colleagues, the Vitamin-D3 supplementation found to reduce migraine attacks in the migraine patients. Vitamin D shows a substantial role in managing various kinds of pain conditions. It is evident from previous studies that the migraineurs exhibit low levels of vitamin D, and this study examined whether vitamin D supplementation would be advantageous in migraine management or not.

A total of 12 males and 36 females of 18 to 65 years old with migraine were taken and categorized into two groups;100 μg/day D3-Vitamin and placebo. Both groups involved 6 males and 18 females. A 4-week baseline session was planned before randomization to the treatment of 24 weeks. 
Self-reported diaries assessed migraine attacks and related symptoms. Serum levels of both 1,25 (OH)2D and 25 (OH)D were estimated from baseline to week 24. The change in migraine severity, the number of migraine days and the response rate ( 50% or greater reduction in migraine frequency from baseline to week 24) were accounted. The evaluation of HIT-6TM scores, pain sensitivity tests (temporal summation and pressure pain threshold) and migraine-related symptoms were also done.

The treatment group showed a more significant reduction in migraine days from  6.14 ± 3.60 to 3.28 ± 3.24 than placebo (5.72 ± 4.52 to 4.93 ± 3.24). The treatment group also exhibited a low frequency of migraine than the placebo group at 24th week. No significant difference was noticed in pressure pain thresholds, temporal summation, migraine severity and 1,25(OH)2D levels. The D3-Vitamin group exhibited considerably higher levels of 25(OH)D as compared to the placebo group. No side-effects were recorded during the whole investigation.

These findings explain the remarkable role of vitamin D in migraine management, but more extensive studies are needed to validate vitamin D3 as a prophylactic alternative for migraine. 

Source:

Current Medical Research and Opinion

Article:

A randomized, double-blinded, placebo-controlled, parallel trial of vitamin D3supplementation in adult patients with migraine.

Authors:

P. Gazerani et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en
Try: